Literature DB >> 6611340

Transformation by human adenoviruses.

F L Graham, D T Rowe, R McKinnon, S Bacchetti, M Ruben, P E Branton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6611340     DOI： 10.1002/jcp.1041210418

Source DB:  PubMed          Journal:  J Cell Physiol Suppl        ISSN： 0737-1462


× No keyword cloud information.
  7 in total

1.  An immunodominant domain in adenovirus type 2 early region 1A proteins.

Authors:  A S Tsukamoto; B Ferguson; M Rosenberg; I L Weissman; A J Berk
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

2.  KAP1 Is a Host Restriction Factor That Promotes Human Adenovirus E1B-55K SUMO Modification.

Authors:  Carolin Bürck; Andreas Mund; Julia Berscheminski; Lisa Kieweg; Sarah Müncheberg; Thomas Dobner; Sabrina Schreiner
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

3.  PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.

Authors:  P Wimmer; J Berscheminski; P Blanchette; P Groitl; P E Branton; R T Hay; T Dobner; S Schreiner
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

4.  Covalently closed circles of human adenovirus DNA are infectious.

Authors:  F L Graham
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

5.  Epigenetic mechanisms in virus-induced tumorigenesis.

Authors:  Elzbieta Poreba; Justyna Karolina Broniarczyk; Anna Gozdzicka-Jozefiak
Journal:  Clin Epigenetics       Date:  2011-03-23       Impact factor: 6.551

6.  E1A expression dysregulates IL-8 production and suppresses IL-6 production by lung epithelial cells.

Authors:  Arjen van den Berg; Mieke Snoek; Henk M Jansen; René Lutter
Journal:  Respir Res       Date:  2005-09-26

7.  Presence of adenovirus species C in infiltrating lymphocytes of human sarcoma.

Authors:  Karin Kosulin; Franziska Hoffmann; Till Sebastian Clauditz; Waldemar Wilczak; Thomas Dobner
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.